Friday 23 October 2026
Export PCSA’s income statement to Excel — free account
Heatwurx Inc.
PCSA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.0% and free cash flow grew 20.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.79
0.07
−3.76%
Follow PCSA
Heatwurx Inc. (PCSA) P/E ratio
As of 22 October 2026, Heatwurx Inc. (PCSA) trades at a P/E ratio of 1.8×. Over the past ten years it has ranged from 0.0× (June 2026) to 1,068× (July 2017); the current reading is higher than 94% of that period. That is below the Biotechnology industry median of 8.6× and below the Healthcare sector median of 23.6×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2016 | 0.0× | — |
| Dec 2015 | 0.0× | — |
| Sep 2015 | 0.0× | — |
| Mar 2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 1,068×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | n/m |
| LGVN Longeveron Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| JAGX Jaguar Animal Health, Inc. compare | 0.0× |
| PCSA Heatwurx Inc. | 1.8× |
| Biotechnology industry median | 8.6× |
| Healthcare sector median | 23.6× |
| Market median | 18.4× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)